TY - JOUR
T1 - Emerging roles for microRNAs in diabetic microvascular disease
T2 - Novel targets for therapy
AU - Zhang, Yu
AU - Sun, Xinghui
AU - Icli, Basak
AU - Feinberg, Mark W.
N1 - Publisher Copyright:
© 2017 Endocrine Society.
PY - 2017
Y1 - 2017
N2 - Chronic, low-grade systemic inflammation and impaired microvascular function are critical hallmarks in the development of insulin resistance. Accordingly, insulin resistance is a major risk factor for type 2 diabetes and cardiovascular disease. Accumulating studies demonstrate that restoration of impaired function of the diabetic macro- and microvasculature may ameliorate a range of cardiovascular disease states and diabetes-associated complications. In this review, we focus on the emerging role of microRNAs (miRNAs), noncoding RNAs that finetune target gene expression and signaling pathways, in insulin-responsive tissues and cell types important for maintaining optimal vascular homeostasis and preventing the sequelae of diabetes-induced end organ injury.We highlight current pathophysiological paradigms of miRNAs and their targets involved in regulating the diabetic microvasculature in a range of diabetes-associated complications such as retinopathy, nephropathy, wound healing, and myocardial injury. Weprovide an update of the potential use of circulatingmiRNAs diagnostically in type I or type II diabetes. Finally, we discuss emerging delivery platforms for manipulating miRNA expression or function as the next frontier in therapeutic intervention to improve diabetes-associated microvascular dysfunction and its attendant clinical consequences.
AB - Chronic, low-grade systemic inflammation and impaired microvascular function are critical hallmarks in the development of insulin resistance. Accordingly, insulin resistance is a major risk factor for type 2 diabetes and cardiovascular disease. Accumulating studies demonstrate that restoration of impaired function of the diabetic macro- and microvasculature may ameliorate a range of cardiovascular disease states and diabetes-associated complications. In this review, we focus on the emerging role of microRNAs (miRNAs), noncoding RNAs that finetune target gene expression and signaling pathways, in insulin-responsive tissues and cell types important for maintaining optimal vascular homeostasis and preventing the sequelae of diabetes-induced end organ injury.We highlight current pathophysiological paradigms of miRNAs and their targets involved in regulating the diabetic microvasculature in a range of diabetes-associated complications such as retinopathy, nephropathy, wound healing, and myocardial injury. Weprovide an update of the potential use of circulatingmiRNAs diagnostically in type I or type II diabetes. Finally, we discuss emerging delivery platforms for manipulating miRNA expression or function as the next frontier in therapeutic intervention to improve diabetes-associated microvascular dysfunction and its attendant clinical consequences.
UR - http://www.scopus.com/inward/record.url?scp=85018178667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018178667&partnerID=8YFLogxK
U2 - 10.1210/er.2016-1122
DO - 10.1210/er.2016-1122
M3 - Review article
C2 - 28323921
AN - SCOPUS:85018178667
SN - 0163-769X
VL - 38
SP - 145
EP - 168
JO - Endocrine reviews
JF - Endocrine reviews
IS - 2
ER -